Endovascular stroke therapy with the Aperio thrombectomy device

Area of Science:

• Neurology
• Interventional Neuroradiology
• Vascular Surgery

Background:

• Pharmaceutical therapy for acute ischemic stroke has limitations in treating large vessel occlusions and long thrombi.
• Endovascular treatment offers added value, with the Aperio thrombectomy device showing promise in preliminary studies.
• Clinical evaluation of the Aperio device is crucial for its adoption in acute stroke management.

Purpose of the Study:

• To clinically evaluate the efficacy and safety of the Aperio thrombectomy device.
• To assess the device's performance in reopening occluded cerebral arteries in patients with acute ischemic stroke.

Main Methods:

• A prospective study involving 119 acute stroke patients treated with the Aperio thrombectomy device across nine centers.
• Assessment of target vessel, thrombus characteristics, procedure duration, recanalization rates, and complications.
• Data collected included number of device deployments and use of adjunctive therapies.

Main Results:

• Successful recanalization (TICI 2-3) was achieved in 85% of patients.
• Complete clot removal was observed in the majority of cases, with TICI 3 achieved in 53%.
• Median procedure time was 30 minutes, with a median of 2 deployments; 10% of patients experienced procedural complications.

Conclusions:

• The Aperio thrombectomy device demonstrated effectiveness in reopening occluded cerebral arteries.
• The device appears to be a safe and valuable tool for endovascular treatment of acute ischemic stroke.
• Clinical outcomes support the use of Aperio for improving reperfusion in stroke patients.